Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
Portfolio Pulse from
The new subcutaneous formulation of Sarclisa met its co-primary endpoints in the IRAKLIA phase 3 study for treating relapsed or refractory multiple myeloma. This formulation, administered via an on-body delivery system, showed non-inferiority compared to the intravenous version.
January 09, 2025 | 6:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi's new subcutaneous formulation of Sarclisa met co-primary endpoints in a phase 3 study, showing non-inferiority to the IV version for treating multiple myeloma.
The successful phase 3 study results for Sarclisa's new subcutaneous formulation are likely to positively impact Sanofi's stock as it demonstrates the potential for improved patient experience and treatment efficacy in multiple myeloma, a significant market.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90